8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association between Venom Immunotherapy and Changes in Serum Protein—Peptide Patterns

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Venom immunotherapy (VIT) is administered to allergic patients to reduce the risk of dangerous systemic reactions following an insect sting. To better understand the mechanism of this treatment and its impact on the human organism, we analysed serum proteomic patterns obtained at five time-points from Hymenoptera-venom-allergic patients undergoing VIT. For statistical analyses, patients were additionally divided into two groups (high responders and low responders) according to serum sIgG4 levels. VIT was found to be associated with changes in seven proteins: the fibrinogen alpha chain, complement C4-A, complement C3, filamin-B, kininogen-1, myosin-9 and inter-alpha-trypsin inhibitor heavy chain H1. The number of discriminative m/z (mass-to-charge ratio) features increased up to the 90th day of VIT, which may be associated with the development of immunity after the administration of increased venom doses. It may also suggest that during VIT, there may occur processes involved not only in protein synthesis but also in protein degradation (caused by proteolytic venom components). The results are consistent with measured serum sIgG4 levels, which increased from 2.04 mgA/I at baseline to 7.25 mgA/I at 90 days. Moreover, the major proteomic changes were detected separately in the high responder group. This may suggest that changes in protein–peptide profiles reflect the actual response to VIT.

          Related collections

          Most cited references75

          • Record: found
          • Abstract: found
          • Article: not found

          Non-muscle myosin II takes centre stage in cell adhesion and migration.

          Non-muscle myosin II (NM II) is an actin-binding protein that has actin cross-linking and contractile properties and is regulated by the phosphorylation of its light and heavy chains. The three mammalian NM II isoforms have both overlapping and unique properties. Owing to its position downstream of convergent signalling pathways, NM II is central in the control of cell adhesion, cell migration and tissue architecture. Recent insight into the role of NM II in these processes has been gained from loss-of-function and mutant approaches, methods that quantitatively measure actin and adhesion dynamics and the discovery of NM II mutations that cause monogenic diseases.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Acute-Phase Proteins and Other Systemic Responses to Inflammation

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The development of allergic inflammation.

              Allergic disorders, such as anaphylaxis, hay fever, eczema and asthma, now afflict roughly 25% of people in the developed world. In allergic subjects, persistent or repetitive exposure to allergens, which typically are intrinsically innocuous substances common in the environment, results in chronic allergic inflammation. This in turn produces long-term changes in the structure of the affected organs and substantial abnormalities in their function. It is therefore important to understand the characteristics and consequences of acute and chronic allergic inflammation, and in particular to explore how mast cells can contribute to several features of this maladaptive pattern of immunological reactivity.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Vaccines (Basel)
                Vaccines (Basel)
                vaccines
                Vaccines
                MDPI
                2076-393X
                12 March 2021
                March 2021
                : 9
                : 3
                : 249
                Affiliations
                [1 ]Faculty of Health Sciences, The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz, 62-800 Kalisz, Poland; jkamatysiak@ 123456gmail.com
                [2 ]Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780 Poznań, Poland; eliza.matuszewska@ 123456ump.edu.pl
                [3 ]Department of Immunology and Allergy, Medical University of Lodz, 92-213 Łódź, Poland; marek.kowalski@ 123456csk.umed.lodz.pl (M.L.K.); slawomir.kosinski@ 123456csk.umed.lodz.pl (S.W.K.); ewasm@ 123456csk.umed.lodz.pl (E.S.-S.)
                Author notes
                [* ]Correspondence: jmatysiak@ 123456ump.edu.pl
                [†]

                Contributed equally to this work and should be considered joint first authors.

                Author information
                https://orcid.org/0000-0002-2475-1066
                https://orcid.org/0000-0002-5765-2603
                https://orcid.org/0000-0002-9993-1504
                Article
                vaccines-09-00249
                10.3390/vaccines9030249
                8001044
                04c129c3-033f-4f12-9047-f881d078944a
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 03 February 2021
                : 10 March 2021
                Categories
                Article

                hymenoptera venom allergy,maldi-tof ms,protein–peptide profiling,proteomics,venom immunotherapy

                Comments

                Comment on this article